-
Historic Victory: Duchenne Added to the Recommended Uniform Screening Panel (RUSP)
Today marks a monumental victory for the Duchenne community. The U.S. Department of Health and
-
FDA designation highlights new treatment approach for DMD
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to (Z)-endoxifen for Duchenne
-
Navigating College Scholarships and Financial Assistance with a Disability
Like many high school students, students with neuromuscular diseases may be looking at college as
-
Insights by Ira: Mission Complete
Just four days prior to my inaugural public engagement as National Ambassador in 2024, I
-
Dyne, citing positive trial data, to ask FDA to approve DMD therapy
Dyne Therapeutics said it plans to ask the U.S. Food and Drug Administration (FDA) to
-
My hope for the FSHD community this Advent season
Advent is the beginning of the church year for Christians. What better way to start
-
Dyne announces positive topline results from Phase 1/2 trial of z-rostudirsen in Duchenne amenable to skipping exon 51
As an early investor in Dyne Therapeutics, we are pleased to share their exciting news
-
New trial results highlight gains in arm and heart function for DMD
In the Phase 3 HOPE-3 clinical trial, the experimental cell therapy deramiocel outperformed a placebo
-
Satellos receives clearance by FDA to initiate Phase 2 study in Duchenne
Satellos Biosciences has received Investigational New Drug (IND) clearance from the FDA, as well as
-
In Case You Missed It…
Quest Media is an innovative, adaptive lifestyle platform from MDA. With the power of this
